Cetera Investment Advisers Sells 2,707 Shares of Denali Therapeutics Inc. $DNLI

Cetera Investment Advisers lowered its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 11.9% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 19,993 shares of the company’s stock after selling 2,707 shares during the quarter. Cetera Investment Advisers’ holdings in Denali Therapeutics were worth $272,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the stock. SG Americas Securities LLC boosted its position in Denali Therapeutics by 339.6% during the 1st quarter. SG Americas Securities LLC now owns 48,365 shares of the company’s stock valued at $658,000 after acquiring an additional 37,362 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Denali Therapeutics by 4.2% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 85,075 shares of the company’s stock valued at $1,733,000 after purchasing an additional 3,411 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Denali Therapeutics during the first quarter valued at approximately $254,000. GAMMA Investing LLC boosted its position in shares of Denali Therapeutics by 253.8% during the first quarter. GAMMA Investing LLC now owns 7,953 shares of the company’s stock valued at $108,000 after purchasing an additional 5,705 shares in the last quarter. Finally, First Trust Advisors LP grew its stake in Denali Therapeutics by 260.9% in the fourth quarter. First Trust Advisors LP now owns 65,442 shares of the company’s stock worth $1,334,000 after purchasing an additional 47,308 shares during the period. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Denali Therapeutics Stock Down 2.0%

Shares of Denali Therapeutics stock opened at $14.51 on Thursday. The company has a 50-day simple moving average of $14.28 and a two-hundred day simple moving average of $15.18. The stock has a market capitalization of $2.12 billion, a PE ratio of -5.18 and a beta of 1.36. Denali Therapeutics Inc. has a 52-week low of $10.57 and a 52-week high of $33.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.27 and a current ratio of 10.27.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.02. During the same quarter in the prior year, the company posted ($0.59) EPS. On average, analysts anticipate that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have commented on DNLI shares. Wedbush lowered their price objective on Denali Therapeutics from $32.00 to $30.00 and set an “outperform” rating for the company in a research report on Wednesday, May 7th. William Blair upgraded shares of Denali Therapeutics to a “strong-buy” rating in a research note on Thursday, April 24th. Bank of America dropped their price objective on shares of Denali Therapeutics from $28.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, May 19th. Robert W. Baird cut their price objective on shares of Denali Therapeutics from $30.00 to $29.00 and set an “outperform” rating on the stock in a report on Thursday, May 8th. Finally, TD Cowen raised shares of Denali Therapeutics to a “strong-buy” rating in a research note on Monday, July 28th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $33.62.

Insider Buying and Selling at Denali Therapeutics

In other news, insider Alexander O. Schuth sold 2,937 shares of the company’s stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total transaction of $39,884.46. Following the transaction, the insider directly owned 242,346 shares of the company’s stock, valued at $3,291,058.68. This represents a 1.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Ryan J. Watts sold 495,282 shares of the stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $15.00, for a total value of $7,429,230.00. Following the sale, the chief executive officer directly owned 253,071 shares in the company, valued at $3,796,065. This trade represents a 66.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 501,962 shares of company stock worth $7,520,799. Insiders own 12.50% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.